Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories.
Clin Diagn Lab Immunol. 2000 May;7(3):352-9. Unique Identifier : AIDSLINE MED/20261939 Reimann KA; Chernoff M; Wilkening CL; Nickerson CE; Landay AL; Division of Viral Pathogenesis, Beth Israel Deaconess Medical; Center, Harvard Medical School, Boston, MA 02115, USA.; kreimann@caregroup.harvard.edu
Abstract:
Human immunodeficiency virus type 1 (HIV-1) infection results in impaired immune function that can be measured by changes in immunophenotypically defined lymphocyte subsets and other in vitro functional assays. These in vitro assays may also serve as early indicators of efficacy when new therapeutic strategies for HIV-1 infection are being evaluated. However, the use of in vitro assays of immune function in multicenter clinical trials has been hindered by their need to be performed on fresh specimens. We assessed the feasibility of using cryopreserved peripheral blood mononuclear cells (PBMC) for lymphocyte immunophenotyping and for lymphocyte proliferation at nine laboratories. In HIV-1-infected patients with moderate CD4(+) lymphocyte loss, the procedures of density gradient isolation, cryopreservation, and thawing of PBMC resulted in significant loss of CD19(+) B cells but no measurable loss of total T cells or CD4(+) or CD8(+) T cells. No significant changes were seen in CD28(-) CD95(+) lymphocytes after cell isolation and cryopreservation. However, small decreases in HLA-DR(+) CD38(+) lymphocytes and of CD45RA(+) CD62L(+) were observed within both the CD4(+) and CD8(+) subsets. Fewer than 10% of those specimens that showed positive PBMC proliferative responses to mitogens or microbial antigens lost their responsiveness after cryopreservation. These results support the feasibility of cryopreserving PBMC for immunophenotyping and functional testing in multicenter AIDS clinical trials. However, small changes in selected lymphocyte subsets that may occur after PBMC isolation and cryopreservation will need to be assessed and considered in the design of each clinical trial.
Keywords: JOURNAL ARTICLE Acquired Immunodeficiency Syndrome/DIAGNOSIS/*IMMUNOLOGY Antigens, CD28/ANALYSIS Antigens, CD3/ANALYSIS Antigens, CD4/ANALYSIS Antigens, CD45/ANALYSIS Antigens, CD8/ANALYSIS Antigens, CD95/ANALYSIS Antigens, Differentiation/ANALYSIS Cell Separation/METHODS Cell Survival/IMMUNOLOGY Clinical Trials/METHODS Cryopreservation/*METHODS Ficoll Human HIV-1/*IMMUNOLOGY Immunophenotyping/*METHODS L-Selectin/ANALYSIS Lymphocyte Subsets/CYTOLOGY/*IMMUNOLOGY/VIROLOGY Multicenter Studies/METHODS NAD+ Nucleosidase/ANALYSIS Retrospective Studies Support, U.S. Gov't, P.H.S.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
